Infliximab for psoriasis

被引：81
作者：
Gottlieb, AB [1 ]
机构：
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Clin Res Ctr, New Brunswick, NJ 08901 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2003年 / 49卷 / 02期
关键词：
D O I：
10.1016/S0190-9622(03)01143-5
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
This review summarizes the use of inflximab in psoriasis and other immune-mediated inflammatory disorders (IMIDs). The magnitude and speed of the response to infliximab monotherapy of moderate to severe psoriasis vulgaris is substantial, being similar to those achieved with cyclosporin. In contrast with cyclosporin, clinical improvement after the initial 3 intravenous influsions of infliximab is maintained for as long as 6 months in approximately half the patients with the absence of any additional treatment. Additionally, infliximab monotherapy normalizes keratinocyte proliferation and differentiation and markedly decreases epidermal inflammation. These results provide a convincing argument for the role of TNF-alpha in the pathogenesis of psoriasis and for the clinical development of infliximab for the treatment of psoriasis.
引用
收藏
页码：S112 / S117
页数：6
相关论文
共 33 条
  • [1] Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
    Chaudhari, U
    Romano, P
    Mulcahy, LD
    Dooley, LT
    Baker, DG
    Gottlieb, AB
    [J]. LANCET, 2001, 357 (9271) : 1842 - 1847
  • [2] INCREASED EXPRESSION OF ADHESION RECEPTORS IN BOTH LESIONAL AND NON-LESIONAL PSORIATIC SKIN
    DEBOER, OJ
    WAKELKAMP, IMMJ
    PALS, ST
    CLAESSEN, N
    BOS, JD
    DAS, PK
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 1994, 286 (06) : 304 - 311
  • [3] ELEVATED TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) BIOLOGICAL-ACTIVITY IN PSORIATIC SKIN-LESIONS
    ETTEHADI, P
    GREAVES, MW
    WALLACH, D
    ADERKA, D
    CAMP, RDR
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1994, 96 (01) : 146 - 151
  • [4] SEVERE PSORIASIS - ORAL THERAPY WITH A NEW RETINOID
    FREDRIKSSON, T
    PETTERSSON, U
    [J]. DERMATOLOGICA, 1978, 157 (04): : 238 - 244
  • [5] T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice
    Gilhar, A
    David, M
    Ullmann, Y
    Berkutski, T
    Kalish, RS
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 109 (03) : 283 - 288
  • [6] Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α
    Gorman, JD
    Sack, KE
    Davis, JC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (18) : 1349 - 1356
  • [7] Clinical research helps elucidate the role of tumor necrosis factor-α in the pathogenesis of T1-mediated immune disorders:: use of targeted immunotherapeutics as pathogenic probes
    Gottlieb, AB
    [J]. LUPUS, 2003, 12 (03) : 190 - 194
  • [8] Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
    Gottlieb, AB
    Masud, S
    Ramamurthi, R
    Abdulghani, A
    Romano, P
    Chaudhari, U
    Dooley, LT
    Fasanmade, AA
    Wagner, CL
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 48 (01) : 68 - 75
  • [9] Psoriasis as a model for T-cell-mediated disease - Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody
    Gottlieb, AB
    Krueger, JG
    Wittkowski, K
    Dedrick, R
    Walicke, PA
    Garovoy, M
    [J]. ARCHIVES OF DERMATOLOGY, 2002, 138 (05) : 591 - 600
  • [10] GOTTLIEB AB, 2003, IN PRESS DERMATOLOGI
1234